Defense Archives - EverGlade

Defense

BARDA Issues RFP Under Project BioShield for 2-PAM Autoinjectors to Strengthen Chemical Threat Preparedness 

Leave a Comment / All Posts, BARDA, Defense, Life Sciences / By

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR), has released a Request for Proposals (RFP) for 2-PAM Autoinjectors for Project BioShield. The RFP supports late-stage clinical development, regulatory approval, procurement, and delivery of pralidoxime, also known as 2-PAM, autoinjectors for the treatment of organophosphate (OP) […]

BARDA Issues RFP Under Project BioShield for 2-PAM Autoinjectors to Strengthen Chemical Threat Preparedness  Read More »

DARPA and NSF Launch AI Forge Initiative for University-Led National Security AI Research

Leave a Comment / All Posts, DARPA, Defense, Emerging Technologies / By

Download the Solicitation The Defense Advanced Research Projects Agency (DARPA), in partnership with the National Science Foundation (NSF) and the Center for AI Standards and Innovation (CAISI) at the National Institute of Standards and Technology (NIST), has released a Request for Information (RFI) for the AI Forge Program. This initiative seeks to identify the capabilities

DARPA and NSF Launch AI Forge Initiative for University-Led National Security AI Research Read More »

DARPA Releases TA1/TA2 Solicitation for RAPIID Blood Analog Systems for Far-Forward Trauma Care

Leave a Comment / All Posts, DARPA, Defense, Life Sciences / By

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has released Program Solicitation DARPA-PS-26-124 for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. RAPIID aims to develop a deployable blood analog system capable of providing the life-saving functions of stored whole blood without requiring cold-chain storage or donor logistics. This

DARPA Releases TA1/TA2 Solicitation for RAPIID Blood Analog Systems for Far-Forward Trauma Care Read More »

MCDC RFI mNGS Solutions

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

MCDC-RFI-Agnostic-Metagenomic-Next-Generation-Sequencing-for-Clinical-Diagnostics Overview of Solicitation The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI) in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has released a Request for Information (RFI) titled Agnostic Metagenomic Next-Generation Sequencing (mNGS) for Clinical Diagnostics. Unlike traditional targeted assays, which require

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection Read More »

MCDC RFI Host-Based Diagnostics

MCDC’s Host-Based Diagnostics for Acute Infections RFI

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

MCDC Request for Information HOST-BASED DIAGNOSTICS Final A Shift Toward Host-Response Diagnostics The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has released a Request for Information (RFI) titled Host-Based Diagnostics for Acute Infections. Issued in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND),

MCDC’s Host-Based Diagnostics for Acute Infections RFI Read More »

MCDC Host-Directed Therapeutics Initiative

MCDC’s Host-Directed Therapeutics Initiative

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

The Medical Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has issued a Request for Information (RFI) focused on “Host-Directed Medical Countermeasures.” This effort, led in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), represents an early step toward shaping a

MCDC’s Host-Directed Therapeutics Initiative Read More »

Scroll to Top